| Budget Amount *help |
¥14,040,000 (Direct Cost: ¥10,800,000、Indirect Cost: ¥3,240,000)
Fiscal Year 2009: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2008: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2007: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
|
|---|
| Research Abstract |
To realize novel protein supplementation therapy for neuronal diseases, we have developed systems for AAV vector production and vector-producing cells. By using effective ion-exchange adsorbers, improved purification of vector particles was investigated. In addition to the step-gradient ultracentrifugation procedure, dual ion-exchange procedures enhanced removal of the empty capsids to realize highly-purified vector production at hand. As an application for the AAV-mediated protein supplementation therapy, therapeutic effects of anti-inflammatory treatment on the mice stroke model were successfully demonstrated. Furthermore, vector-producing mesenchymal stem cells to target glioma were developed to target seat of disease with improved anti-tumor effects in vivo.
|
